ITGAL, ITGB2: Integrin alpha-L/beta-2 (LFA-1)
Complex in Homo sapiens that 3 drugs act on.
- Drugs that act on it: 3
- Approved: 2
- In phases 1 to 3: 1
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on ITGAL, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
- Antibody 2
| Lifitegrast | Approved | Bausch & Lomb | Small molecule | AntagonistIntegrin alpha-L/beta-2 (LFA-1) antagonist | 5 |
| EfalizumabWithdrawn | Approved | Merck KGaA, Darmstadt, Germany | Antibody | InhibitorIntegrin alpha-L/beta-2 (LFA-1) inhibitor | 1 |
| Rovelizumab | Phase 2 | — | Antibody | AntagonistIntegrin alpha-L/beta-2 (LFA-1) antagonist | 0 |
| Clinical Evaluation of Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease Using In Vivo Confocal Microscopy | Lifitegrast | Phase 4 | Not yet recruiting | Toyos Clinic | May 1, 2026 |
| This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye | Lifitegrast | Phase 4 | Not yet recruiting | Pittsburgh Research Institute | Mar 24, 2026 |
| Switching From Xiidra to TRYPTYR | Lifitegrast | Phase 4 | Not yet recruiting | Southern College of Optometry | Dec 5, 2025 |
| Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease | Lifitegrast | Phase 3 | Recruiting | Lunan Better Pharmaceutical Co., LTD. | Mar 17, 2025 |
| Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications | Lifitegrast | — | Recruiting | University of California, Los Angeles | Apr 21, 2020 |
| PsoBest - The German Psoriasis Registry | Efalizumab | — | Recruiting | Universitätsklinikum Hamburg-Eppendorf | May 7, 2013 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364172, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets